Cancer Prevention

Cancer prevention means reducing your risk of ever developing cancer — through steps like behaviour and habit modification like quitting tobacco, limiting alcohol, vaccination and weight management — while cancer screening looks for cancer or pre-cancerous changes in people who have no symptoms yet, such as mammography or colonoscopy. The two work together: prevention lowers the odds a cancer starts, and screening catches it at its earliest, most treatable stage if it does. At BeyondAge, both sit inside one personalised, physician-led plan rather than being treated as separate, one-off events.

A 2026 analysis in Nature Medicine, led by IARC (the WHO's cancer research agency), found that close to 38% of new cancer cases worldwide — around 7.1 million cases a year — are attributable to 30 modifiable risk factors, with tobacco use the single largest contributor at over 15%, followed by chronic infections and alcohol. A substantial share of cancer risk is genuinely within your control, even though family history and biology also play a role.

Warning signs vary by cancer type, but persistent, unexplained changes are always worth investigating: a new lump, unexplained weight loss, changes in bowel or bladder habits, a persistent cough or hoarseness, abnormal bleeding, a sore that doesn't heal, or a mole that changes shape or colour. Most of these have benign causes, but because early-stage cancer often has no symptoms at all, routine risk-based screening — not just watching for symptoms — is what catches disease earliest.

The tests you need depend on your age, sex, family history and lifestyle risk factors, but commonly recommended essentials include mammography for women from their 40s, Pap smear with HPV co-testing from the mid-20s, colorectal screening (colonoscopy or stool-based testing) from age 45, and low-dose CT chest for long-term heavy smokers meeting specific risk criteria. These guidelines, set by bodies like the USPSTF, are a starting point — BeyondAge's risk assessment weighs them against your individual history and risk factors, rather than applying a generic checklist. Not every test suits every person: some, like ovarian cancer or whole-body screening, aren't recommended for average-risk individuals at all and are reserved for those with a confirmed elevated risk.

Not automatically, but it's worth discussing with a genetic counsellor. A pattern such as cancer in multiple close relatives, cancer diagnosed at a young age, or combinations like breast and ovarian cancer in the same family can suggest an inherited mutation, most commonly in genes like BRCA1/2 or the Lynch syndrome genes. Genetic testing identifies these mutations so screening and prevention can start earlier and more intensively; it's one part of BeyondAge's advanced hereditary cancer risk panel, always paired with counselling to interpret what a result actually means for you.

Yes. Alongside not smoking, maintaining a healthy weight, limiting alcohol, staying physically active and eating a fibre-rich, plant-forward diet are among the most consistently evidence-backed ways to lower cancer risk, particularly for colorectal, breast and endometrial cancers. The IARC Nature Medicine 2026 analysis found high body mass index and insufficient physical activity among the leading modifiable contributors to global cancer burden, alongside tobacco, alcohol and infections. These changes reduce risk; they don't eliminate it, which is why lifestyle change and risk-based screening work best together.

An MCED test is a single blood draw that screens for signals — typically fragments of tumour DNA — associated with multiple cancer types at once, several of which have no standard screening test today. It's a genuinely promising, fast-evolving technology, but it remains investigational: no MCED test currently holds full regulatory approval as a stand-alone screening tool, and no major body — USPSTF, ASCO or NCCN — yet recommends it for population-level screening, given open questions on false positives and overdiagnosis. A positive signal always needs confirmatory diagnostic work-up. At BeyondAge, MCED testing sits within our advanced diagnostics tier, offered only to complement — never replace — guideline-based essential screening.

Because cancer's treatability drops sharply once it spreads. American Cancer Society data show that when breast, colon or cervical cancer is caught at the localized stage, 5-year survival is above 90% (over 99% for localized breast cancer) — but once it has spread to distant organs, survival falls to roughly 13-32% depending on cancer type. This gap is the entire rationale for structured, risk-based screening: catching disease before it spreads is often the single biggest determinant of outcome, more than the treatment that follows.